Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate

Journal of Medicinal Chemistry

Volumn 45, Issue 14, 2002, Pages 2994-3008

  Regan, John ^a   Moss, Neil ^a   Pargellis, Chris ^a   Pav, Sue ^a   Proto, Alfred ^a   Swinamer, Alan ^a   Tong, Liang ^a   Torcellini, Carol ^a   Breitfelder, Steffen ^a   Cirillo, Pier ^a   Gilmore, Thomas ^a   Graham, Anne G ^a   Hickey, Eugene ^a   Klaus, Bernhard ^a   Madwed, Jeffrey ^a   Moriak, Monica ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 TERT BUTYL 2 (4 TOLYL 2H PYRAZOL 3 YL)] 3 [4 (2 MORPHOLIN 4 YL ETHOXY)NAPHTHALEN 1 YL]UREA; 4 (4 FLUOROPHENYL) 2 (5 METHYL 5 MORPHOLINOCARBONYL 1,3 DIOXAN 2 YL) 5 (4 PYRIDINYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 6 AMINO 2 (4 FLUOROPHENYL) 4 METHOXY 3 (4 PYRIDYL) 1H PYRROLO[2,3 B]PYRIDINE; ADENOSINE TRIPHOSPHATE; DORAMAPIMOD; EO 1428; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; RO 3201195; SB 24235; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING, COMPETITIVE; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FEMALE; FLUORESCENCE; HUMANS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; NAPHTHALENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA; UREA;

EID: 0037019275     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020057r     Document Type: Article

References (59)

1. Inflammatory cytokines: Interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases
2. Potential of p38 inhibitors in the treatment of rheumatoid arthritis
3. Role of cytokines in rheumatoid arthritis
4. Etanercept: A review of its use in rheumatoid arthritis
5. Etanercept: Therapeutic use in patients with rheumatoid arthritis
6. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
7. Cytokines in rheumatoid arthritis: Trials and tribulations
8. Tumour necrosis factor-alpha blockade: A new era for effective management of rheumatoid arthritis
9. Infliximab for the treatment of fistulas in patients with Crohn's disease
10. Review article: Efficacy of infliximab in Crohn's disease-induction and maintenance of remission
11. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
12. p38 MAPK signalling cascades in inflammatory disease
13. The p38 signal transduction pathway. Activation and function
14. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials
15. Inhibition of p38 MAP kinase as a therapeutic strategy
16. p38 mitogen-activated protein kinase as a target for drug discovery
17. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases
18. 1-Substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency
19. Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity
20. Phenoxypyrimidine inhibitors of p38 kinase: Synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperdin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles
21. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes
22. Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity
23. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function
24. Suppression of ex-vivo cytokine production by SB-242235, a selective inhibitor of p38 MAP kinase
25. Inhibitors of p38 Kinase
26. New inhibitors of p38 kinase
27. Protein kinase inhibitors: Emerging pharmacophores 1997-2000
28. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase
29. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral antiarthritic efficacy
30. Pyrroles and other heterocycles as inhibitors of p38 kinase
31. SAR of 4-hydroxypiperidine and hydroxvalkyl substituted heterocycles as novel p38 map kinase inhibitors
32. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo-[2,3-b]pyridine (RWJ 68354): A potent and selective p38 kinase inhibitor
33. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
34. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated proteinkinase inhibitor, in healthy human volunteers
35. Discovery of VX-745: A novel orally bioavailable and selective p38 MAP kinase inhibitor
36. The discovery of RO3201195, a novel and selective inhibitor of p38 kinase
37. Activities of the p38 MAP kinase inhibitor, EO1428, in three animal models of dermatitis
38. Amide derivatives useful for the treatment of diseases mediated by cytokines
39. 1-Phenyl-5-pyrazolyl ureas: Potent and selective p38 kinase inhibitors
40. Discovery of a new class of p38 kinase inhibitors
41. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: Thienyl, furyl and pyrrolyl ureas
42. Inhibition of p38 map kinase by utilizing a novel allosteric binding site
43. Addition of arylmetallics to azodicarboxylates: A novel synthesis of arylhydrazines by aromatic hydrazination
44. Stereoselective, mild reduction of tosylhydazones with sodium cyanoborohydride in acidic media
45. An efficient one-step synthesis of 3-oxoalkanenitriles
46. The synthesis of 5-amino-3-tert-butylisothiazole and 3-amino-5-tert-butylisothiazole
47. Synthesis of peptide isocyanates and isothiocyanates
48. A highly efficient and general N-mono-methylation of functionalized primary amines via formylation-borane: Dimethyl sulfide reduction
49. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
50. 2,4,5-Triarylimidazole inhibitors of IL-1 biosynthesis
51. The gauche effect. Some stereochemical consequences of adjacent electron pairs and polar bonds
52. Antiinflammatory effects of a p38 mitogen activated protein kinase inhibitor during human en dotoxemia
53. Twisted Si=N bonds: Matrix isolation of bridgehead silanimines
54. Crystallization and preliminary crystallographic analysis of recombinant human p38 MAP kinase